Quantifying the impact of vaccines on antibiotic use for respiratory infections in children
量化疫苗对儿童呼吸道感染抗生素使用的影响
基本信息
- 批准号:10606403
- 负责人:
- 金额:$ 4.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:Acute respiratory infectionAddressAntibiotic ResistanceAntibioticsBacteriaBacterial Antibiotic ResistanceBig Data MethodsBronchitisCaringCessation of lifeChildChildhoodClinical TrialsCommunicable DiseasesDataData MartData SourcesDatabasesDecision MakingDevelopmentDoseEffectivenessEmergency department visitEpidemiologic MethodsEpidemiologistEpidemiologyFellowshipFutureGoalsGuidelinesHealthHealthcare SystemsHospitalsHumanInfectionInfection preventionInfluenzaInfluenza vaccinationLicensingLifeMedicalMethodsModern MedicineMorbidity - disease rateNational Ambulatory Medical Care SurveyObservational StudyOrganismOtitis MediaOutpatientsPatientsPersonsPharmaceutical PreparationsPharmacy facilityPhysicians&apos OfficesPneumococcal conjugate vaccinePoliciesPolicy MakingPopulation Attributable RisksPrivatizationPublic Health SchoolsRecommendationRecurrenceResearchResearch PersonnelResearch PriorityResistanceResourcesRespiratory Tract InfectionsRespiratory syncytial virusSamplingSerotypingStatistical MethodsStreptococcusStreptococcus pneumoniaeStreptococcus pyogenesStudy modelsSurveysTherapeuticTrainingUncertaintyVaccinationVaccine ResearchVaccinesViralVirusVisitWorkage groupcombatexperienceimprovedinfluenza virus vaccineinfluenzaviruslarge scale datamortalitynovelpathogenpreventresearch and developmentrespiratory pathogenskillsuptakevaccination strategyvaccine candidatevaccine developmentvaccine strategy
项目摘要
PROJECT SUMMARY
Antibiotic resistance is a significant threat to human health. Human therapeutic antibiotic use, the majority of
which occurs in outpatient settings for non-severe infections, is a major, modifiable driver of resistance. Acute
respiratory infections (ARIs) account for large proportions of outpatient antibiotic use and vaccines have been
recognized as important mechanisms to combat antibiotic use and resistance, especially for ARIs. However,
uncertainties remain in understanding the contributions of common respiratory pathogens to outpatient antibiotic
use and quantifying the full potential of vaccines to reduce antibiotic use, impeding informed policymaking and
priority-setting for vaccine research and development. The proposed research addresses these gaps in the
context of both existing and pipeline vaccines for three common respiratory pathogens in children: Streptococcus
pneumonaie, influenza virus, and respiratory syncytial virus (RSV). The objective of this proposed work is to
estimate impacts of both existing and potential vaccine strategies on outpatient antibiotic prescriptions for ARIs
in children. More specifically, the research focuses on the following aims: 1) estimate the attributable fractions
of ARI-associated pediatric outpatient antibiotic use due to vaccine-preventable respiratory pathogens; 2)
evaluate the impact of pneumococcal vaccination strategies on outpatient antibiotic use for ARIs in children; and
3) evaluate the impact of viral (influenza, RSV) vaccination strategies on outpatient antibiotic use for ARIs in
children. This project focuses specifically on ARIs in children as they are both major drivers of outpatient antibiotic
use and targets of existing and pipeline vaccines. The work will leverage multiple, complementary, large-scale
data sources including both claims data (Optum Clinformatics, IBM MarketScan) and nationally-representative
outpatient medical surveys (National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical
Care Survey), each with millions of pediatric ARI visits and outpatient antibiotic prescriptions per year, to address
these aims. The breadth of data and statistical and epidemiologic methods used in this proposed research will
enable a novel and comprehensive understanding of the potential for vaccines to reduce outpatient antibiotic
use for ARIs in children. This work will inform urgently-needed antibiotic resistance mitigation strategies and
priority setting and decision-making for vaccine research/development and policy. The proposed methods will
further provide a novel framework for evaluating current and future vaccines as outpatient infections and
antibiotic use are not commonly considered endpoints, despite their substantial burden. This research will be
enhanced by and complementary to my proposed training plan, which emphasizes development and experience
in epidemiologic and statistical methods, big data methods and applications, subject matter expertise, and
additional skills necessary for me to become an independent investigator. UC Berkeley, particularly the School
of Public Health, provides extensive resources and support to enable me to successfully complete the proposed
fellowship and fulfill my long-term goal of becoming a research-oriented infectious disease epidemiologist.
项目概要
抗生素耐药性是对人类健康的重大威胁。人类治疗性抗生素的使用,大多数
它发生在门诊环境中的非严重感染,是耐药性的一个主要的、可改变的驱动因素。急性
呼吸道感染(ARIs)在门诊抗生素使用中占很大比例,并且疫苗已被
被认为是对抗抗生素使用和耐药性的重要机制,特别是对于 ARI。然而,
了解常见呼吸道病原体对门诊抗生素的贡献仍存在不确定性
使用和量化疫苗减少抗生素使用的全部潜力,阻碍明智的决策和
确定疫苗研究和开发的优先顺序。拟议的研究解决了这些差距
针对儿童三种常见呼吸道病原体的现有和正在研发的疫苗的背景:链球菌
肺炎、流感病毒和呼吸道合胞病毒(RSV)。这项拟议工作的目标是
估计现有和潜在疫苗策略对 ARI 门诊抗生素处方的影响
在儿童中。更具体地说,该研究重点关注以下目标:1)估计归因分数
由于疫苗可预防的呼吸道病原体而导致 ARI 相关儿科门诊抗生素使用的情况; 2)
评估肺炎球菌疫苗接种策略对儿童急性呼吸道感染门诊抗生素使用的影响;和
3) 评估病毒(流感、RSV)疫苗接种策略对 ARI 门诊抗生素使用的影响
孩子们。该项目特别关注儿童急性呼吸道感染,因为它们都是门诊抗生素的主要驱动因素
现有和管道疫苗的用途和目标。这项工作将利用多种、互补、大规模的
数据源包括索赔数据(Optum Clinformatics、IBM MarketScan)和全国代表性数据
门诊医疗调查(国家流动医疗调查和国家医院流动医疗调查)
护理调查),每年都有数以百万计的儿科 ARI 就诊和门诊抗生素处方,以解决
这些目标。这项拟议研究中使用的数据以及统计和流行病学方法的广度将
使人们能够对疫苗减少门诊抗生素使用的潜力有一个新颖而全面的了解
用于儿童急性呼吸道感染。这项工作将为迫切需要的抗生素耐药性缓解策略提供信息,
疫苗研究/开发和政策的优先事项设定和决策。所提出的方法将
进一步提供了一个新的框架,用于评估当前和未来的疫苗作为门诊感染和
尽管抗生素的使用造成了巨大的负担,但通常不被视为终点。这项研究将
我提出的强调发展和经验的培训计划得到了加强和补充
流行病学和统计方法、大数据方法和应用、主题专业知识,以及
我成为一名独立调查员所需的额外技能。加州大学伯克利分校,特别是学校
公共卫生部门提供了广泛的资源和支持,使我能够成功完成拟议的
奖学金并实现我成为一名研究型传染病流行病学家的长期目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laura King其他文献
Laura King的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Bacteriophage as a predictive biomarker in chronic Pseudomonas airway disease
噬菌体作为慢性假单胞菌气道疾病的预测生物标志物
- 批准号:
10723956 - 财政年份:2023
- 资助金额:
$ 4.38万 - 项目类别:
Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections
用于治疗耐抗生素肺炎克雷伯菌感染的先导治疗噬菌体混合物的优化、制造和测试
- 批准号:
10674294 - 财政年份:2023
- 资助金额:
$ 4.38万 - 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
- 批准号:
10716654 - 财政年份:2023
- 资助金额:
$ 4.38万 - 项目类别:
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms
开发一类针对碳青霉烯类耐药革兰氏阴性生物的新型肽抗生素
- 批准号:
10674131 - 财政年份:2023
- 资助金额:
$ 4.38万 - 项目类别:
Pathobiology of MRSA-induced Endothelial Permeability and Acute Lung Injury
MRSA 诱导的内皮通透性和急性肺损伤的病理学
- 批准号:
10608606 - 财政年份:2022
- 资助金额:
$ 4.38万 - 项目类别: